How China became the new world leader in clinical trials

Key Points

China has significantly increased its investment in medical research, strengthening its global standing in clinical trials.
The country’s advancements position it to capitalize on weaknesses in the US medical research sector, with billions invested over decades.
Geopolitical factors and local challenges may complicate China’s dominance in the clinical trials landscape.
China's status as a scientific superpower influences both domestic and international research initiatives.

Abstract

After investing decades and billions of yuan in becoming a scientific superpower, China is well placed to benefit from the plight of the US medical research sector. But geopolitical ructions and local idiosyncrasies could complicate this, writes Flynn Murphy

Bookmark

Cite This Study

F. A. Murphy (Fri,) studied this question.

synapsesocial.com/papers/69a76101c6e9836116a2e7ef https://doi.org/https://doi.org/10.1136/bmj.s221

Bookmark